Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Sanderson

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Immunology|January 3, 2013
CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cellsJoseph P Sanderson, Patrick J Brennan, Salah Mansour, et al.
Nature Immunology|November 1, 2011
Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signalsPatrick J Brennan, Raju V V Tatituri, Manfred Brigl, et al.
The Journal of Allergy and Clinical Immunology|July 4, 2006
Activation of T cells by carbamazepine and carbamazepine metabolitesYing Wu, Joseph P Sanderson, John Farrell, et al.
Chemical Research in Toxicology|May 15, 2013
β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosisRosalind E Jenkins, Fiazia S Yaseen, Manal M Monshi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2015
Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid ArthritisSalah Mansour, Anna S Tocheva, Joseph P Sanderson, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver CancerRoslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Oncoimmunology|February 1, 2020
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapyJoseph P Sanderson, Darragh J Crowley, Guy E Wiedermann, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Immunology|January 3, 2013
CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cellsJoseph P Sanderson, Patrick J Brennan, Salah Mansour, et al.
Nature Immunology|November 1, 2011
Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signalsPatrick J Brennan, Raju V V Tatituri, Manfred Brigl, et al.
The Journal of Allergy and Clinical Immunology|July 4, 2006
Activation of T cells by carbamazepine and carbamazepine metabolitesYing Wu, Joseph P Sanderson, John Farrell, et al.
Chemical Research in Toxicology|May 15, 2013
β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosisRosalind E Jenkins, Fiazia S Yaseen, Manal M Monshi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2015
Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid ArthritisSalah Mansour, Anna S Tocheva, Joseph P Sanderson, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver CancerRoslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Oncoimmunology|February 1, 2020
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapyJoseph P Sanderson, Darragh J Crowley, Guy E Wiedermann, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Pageof 3